By Fineline Cube 
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received the upfront payment and finalized the equity transfer of its Swiss partner Windward Bio’s parent company. This follows a licensing deal struck in January 2025 with Harbour BioMed (HKG: 2142) and Windward Bio.
Agreement Details
The agreement centers on HBM9378/SKB378/WIN378, a fully human monoclonal antibody (mAb) targeting thymic stromal lymphopoietin (TSLP), co-developed by Harbour BioMed and Kelun-Biotech. The two companies share global rights equally for the asset. Under the terms of the deal, Windward Bio has secured an exclusive global license (excluding Greater China and select Southeast and West Asian countries) to research, develop, manufacture, and commercialize HBM9378/SKB378/WIN378.
Financial Terms
Harbour BioMed and Kelun-Biotech are eligible to receive up to USD 970 million in upfront and milestone payments, plus tiered royalties ranging from single-digit to double-digit percentages of net sales. Within that, upfront and near-term milestone payments total USD 45 million, comprising cash and equity in Windward Bio’s parent company.-Fineline Info & Tech